ASCO 2026 marked a clear inflection point in oncology. Brooks Hill Partners breaks down the meeting's defining themes — from pan-KRAS inhibitors unlocking treatment in pancreatic cancer, to bispecific antibodies expanding immunotherapy's reach, and ADCs emerging as a cornerstone of next-generation combination strategies. Underlying it all: a growing imperative to translate scientific breakthroughs into globally equitable access.

The surgical robotics market is undergoing its most significant structural shift in over two decades. New FDA clearances for Medtronic, CMR Surgical, and Johnson & Johnson are challenging Intuitive Surgical's long-standing dominance. A Medicare reimbursement change effective January 2026 is accelerating the move of procedures into ambulatory surgery centers. The result: a market that looks fundamentally different from 2024 — and a new competitive battleground forming outside

Medtech deal activity has shifted from broad recovery to concentrated selectivity. Total M&A values climbed from ~$26B in 2023 to ~$61B in 2025, yet fewer deals are driving the numbers. Capital is flowing to milestone-proven assets, deal structures increasingly favor performance-based payments over upfront cash, and portfolio reshaping is accelerating. Here's what the data reveals about where medtech is heading.

Amid rapid scientific progress, familiar targets continue to capture momentum while promising alternatives struggle for visibility. A quiet cognitive bias shapes how opportunities are assessed and prioritized. For companies developing novel science, recognizing this pattern—and designing strategies that anticipate and counter it—will be essential to advancing differentiated programs in a landscape defined by precedent.

Patient journey mapping has transformed how life sciences companies understand and serve patients—but most maps miss a crucial voice: the caregiver. By expanding mapping to capture real-time, diverse patient experiences and integrating caregiver perspectives, companies can design more relevant trials, value-based products, and compelling launch narratives. Including those who guide patients through care not only humanizes development but drives adherence, satisfaction, and co

Federal grant volatility is disrupting early-stage biotech, with programs like CDMRP facing steep cuts and new NIH restrictions limiting access. As delays and cancellations increase, traditional budgeting falls short. This piece explores how scenario-based FP&A helps companies navigate uncertainty, prioritize pipelines, and sustain innovation in a shifting funding landscape.

Pharma’s sales model is shifting toward a strategic hybrid: balancing digital convenience with the enduring influence of in-person engagement. While digital channels offer scalable, flexible access, face-to-face interactions remain the most effective for influencing prescribing behavior. The key to success lies in tailoring the right channel to the right context: drug type, physician preference, and market dynamics all matter.

A fragmented KOL engagement approach can damage credibility, strain relationships, and lead to missed insights. This article explores the value of a harmonized strategy that aligns Medical Affairs, Clinical Development, and Commercial teams to ensure consistent, strategic interactions. It also highlights the rise of Digital Opinion Leaders and the need to engage emerging voices. A coordinated approach not only builds trust with experts but also drives better outcomes and long

The Trump administration is doubling down on its promise of pharmaceutical tariffs, designed to re-shore manufacturing and protect strategic interests. What would it mean for biopharma? More importantly, what would it mean for patients? In this article, we summarize existing perspectives and dive into some less-explored topics, such as clinical trial execution, budget management, and early-stage investment.

GLP-1 therapies transformed obesity & diabetes care and are now being explored for potential breakthroughs in neurological diseases.

AI promised faster drug discovery, lower costs, and reduced risk — but the reality has proven more nuanced. From an 80–90% Phase 1 success rate to high-profile pipeline cuts, this piece looks at where AI has genuinely delivered, where the hype has outpaced the science, and what it will take to build a credible, transparent path forward.

Organs-on-chips are at the forefront of preclinical innovation, promising to usher in a new era of patient-centric drug development.

Explore new targets for CRISPR-based therapeutics, as well as challenges associated with commercialization of these therapies.

A judge's dismissal of Welsh, Carson, Anderson & Stowe from the FTC's antitrust case against US Anesthesia Partners is more than a courtroom footnote, it's a meaningful signal for private equity nationwide. Had WCAS been held liable for its portfolio company's conduct despite its minority stake, the precedent could have chilled investment across life sciences, an industry that depends heavily on private capital to fund innovation. We break down the case and its broader implic

GLP-1 medications have emerged as a powerful weapon against obesity and diabetes, but at nearly $1,000 a month, they're forcing payors and patients into a difficult financial balancing act. This post explores how Medicare, commercial insurers, and employers are grappling with coverage decisions, why some plans are reversing course amid budget concerns, and whether tying access to lifestyle modification programs could offer a sustainable middle ground between innovation and co

Pharmacy Benefit Managers wield outsized influence over what medications cost and how accessible they are, negotiating deals between health plans, drug manufacturers, and pharmacies largely out of public view. This post unpacks how PBMs operate, the biggest criticisms of their business model, including spread pricing and vertical integration among the three companies controlling 79% of the market, and the legislation moving through Congress aimed at bringing more transparency

After a brutal two-year downturn, biotech is showing real signs of life in 2024. A strong start to IPO activity, the XBI's 38% Q4 surge, and a resurgent M&A market, backed by over $500 billion in pharma firepower, are fueling renewed investor optimism. This post breaks down the forces driving the recovery, from anticipated interest rate cuts to pending patent cliffs, and explains why investors, chastened by 2022's downturn, are approaching this cycle with sharper discipline a

Tucked within our gastrointestinal tract, the enteric nervous system quietly does more than regulate digestion; it may also hold a key to cardiovascular health. This post explores the emerging gut-heart axis, examining how the vagus nerve, gut microbiota, and enteric signaling influence blood pressure, inflammation, atherosclerosis, and heart failure. As researchers uncover these connections, therapies targeting the gut microbiome are emerging as promising strategies for prot